Clotblog with Dr Samuel GoldhaberView all posts »
Clear the decks for apixaban!Jun 24, 2011 16:55 EDT
As the population ages and atrial fibrillation becomes more common, the news that another drug—apixaban—has made its first step toward joining the growing field of novel anticoagulants is cause for celebration. What are your thoughts on the preliminary results of the ARISTOTLE trial, which have shown apixaban to be noninferior to warfarin for stroke prevention in AF patients?
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 9:806-817. Available here.
Bristol-Myers Squibb. Eliquis (apixaban) meets primary and key secondary endpoints in phase 3 ARISTOTLE study [press release]. June 22, 2011. Available here.